이재현 교수

Cancer-cell-targeted gene silencing was observed with a magnetic-nanoparticle platform (MEIO, magnetism-engineered iron oxide) on which a fluorescent dye, siRNA, and a RGD-peptide targeting moiety were attached (see picture). The different functionalities enable the macroscopic (magnetic resonance) and microscopic (fluorescence) imaging of target cells. This system may be suitable for concurrent diagnostic and therapeutic applications.

Working together: A “core–satellite” hybrid nanoparticle probe provides highly improved fluorescence and magnetic resonance (MR) imaging capabilities through synergistic enhancement of its respective components. These hybrid nanoprobes can be used for dual-modal fluorescence and MR imaging of neuroblastoma with expressed polysialic acids.

Teamarbeit: Eine „Kern-Satelliten“-Hybridnanopartikel-Sonde ermöglicht dank der synergistischen Verstärkung ihrer Komponenten ein erheblich verbessertes Fluoreszenz- und Magnetresonanz(MR)-Imaging. Diese Hybridnanosonden können für das dual-modale Fluoreszenz- und MR-Imaging von Neuroblastoma mit exprimierten Polysialinsäuren genutzt werden.

Silica nanoparticles (SNPs) are widely used in many scientific and industrial fields despite the lack of proper evaluation of their potential toxicity. This study examined the effects of acute exposure to SNPs, either alone or in conjunction with ovalbumin (OVA), by studying the respiratory systems in exposed mouse models. Three types of SNPs were used: spherical SNPs (S-SNPs), mesoporous SNPs (M-SNPs), and PEGylated SNPs (P-SNPs). In the acute SNP exposure model performed, 6-week-old BALB/c fem

Abstract Eine gezielte Genstummschaltung in Krebszellen gelang mit magnetischen Eisenoxid‐Nanopartikeln (MEIO), an denen ein Fluoreszenzfarbstoff, siRNA sowie ein RGD‐Peptid zur Erkennung von Krebszellen angebracht waren (siehe Bild). Die verschiedenen funktionellen Einheiten ermöglichen eine kombinierte makroskopische (Kernspin‐) und mikroskopische (Fluoreszenz‐)Tomographie der Zielzellen. Dieses System könnte sich für die parallele diagnostische und therapeutische Anwendung eignen. magnified i

Various bio-medical applications of magnetic nanoparti-cles have been explored during the past few decades. As tools that hold great potential for advancing biological sciences, magnetic nanoparticles have been used as platform materials for enhanced magnetic resonance imaging (MRI) agents, biological separation and magnetic drug delivery systems, and magnetic hyperthermia treatment. Furthermore, approaches that integrate various imaging and bioactive moieties have been used in the design of mul

BACKGROUND: Silica nanoparticles (SNPs) can easily enter in respiratory system via inhalation because of their low molecular weight and ease of dispersion. Toxicity and adverse effects of SNPs vary according to the physical characteristics of the particle. METHODS: To evaluate the toxic and adjuvant effects of 3 types of SNPs in the airway system, six-week-old female BALB/c mice were intranasally administered 3 types of SNPs (spherical [S-SNP], mesoporous [M-SNP], and polyethylene glycol-conjuga

Asthma is a chronic inflammatory disease induced by Type 2 helper T cells and eosinophils. Vascular cell adhesion molecule-1 (VCAM-1) has been implicated in recruiting eosinophils and lymphocytes to pathological sites in asthma as a regulatory receptor. Accordingly, monoclonal antibody (mAb) against VCAM-1 may attenuate allergic inflammation and pathophysiological features of asthma. We attempted to evaluate whether a recently developed human anti-VCAM-1 mAb can inhibit the pathophysiological fe

PURPOSE: The PROTIA™ Allergy-Q® enzyme immunoassay (EIA) is a recently developed screening assay for specific immunoglobulin E (sIgE) for multiple allergens. The ImmunoCAP® fluorescent EIA (FEIA) system is the most widely used method for sIgE detection. In this study, we evaluated the performance of the Allergy-Q® system compared to the ImmunoCAP® system. METHODS: We compared the 2 systems using sera from 260 Korean allergy patients suffering from asthma (26.5%), allergic rhinitis (42.3%), atopi